219 related articles for article (PubMed ID: 26160429)
1. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
Kuang Y; El-Khoueiry A; Taverna P; Ljungman M; Neamati N
Mol Oncol; 2015 Nov; 9(9):1799-814. PubMed ID: 26160429
[TBL] [Abstract][Full Text] [Related]
2. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.
Liu M; Zhang L; Li H; Hinoue T; Zhou W; Ohtani H; El-Khoueiry A; Daniels J; O'Connell C; Dorff TB; Lu Q; Weisenberger DJ; Liang G
Hepatology; 2018 Oct; 68(4):1412-1428. PubMed ID: 29774579
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
Jueliger S; Lyons J; Cannito S; Pata I; Pata P; Shkolnaya M; Lo Re O; Peyrou M; Villarroya F; Pazienza V; Rappa F; Cappello F; Azab M; Taverna P; Vinciguerra M
Epigenetics; 2016 Oct; 11(10):709-720. PubMed ID: 27646854
[TBL] [Abstract][Full Text] [Related]
4. β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
Li X; Lin Z; Zhang B; Guo L; Liu S; Li H; Zhang J; Ye Q
Sci Rep; 2016 Feb; 6():21010. PubMed ID: 26867799
[TBL] [Abstract][Full Text] [Related]
5. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
6. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
7. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma.
Deng G; Zeng S; Ma J; Zhang Y; Qu Y; Han Y; Yin L; Cai C; Guo C; Shen H
Sci Rep; 2017 Jan; 7():41616. PubMed ID: 28134289
[TBL] [Abstract][Full Text] [Related]
9. Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma.
Zhang Y; Li Q; Wang J; Cheng F; Huang X; Cheng Y; Wang K
Cancer Lett; 2016 Jul; 377(2):117-25. PubMed ID: 27130669
[TBL] [Abstract][Full Text] [Related]
10. Impaired gap junctions in human hepatocellular carcinoma limit intrinsic oxaliplatin chemosensitivity: A key role of connexin 26.
Yang Y; Zhu J; Zhang N; Zhao Y; Li WY; Zhao FY; Ou YR; Qin SK; Wu Q
Int J Oncol; 2016 Feb; 48(2):703-13. PubMed ID: 26648344
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway.
Li D; Zhang B; Hu C
Acta Biochim Biophys Sin (Shanghai); 2017 Jul; 49(7):581-587. PubMed ID: 28475688
[TBL] [Abstract][Full Text] [Related]
13. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.
Ding ZB; Hui B; Shi YH; Zhou J; Peng YF; Gu CY; Yang H; Shi GM; Ke AW; Wang XY; Song K; Dai Z; Shen YH; Fan J
Clin Cancer Res; 2011 Oct; 17(19):6229-38. PubMed ID: 21825039
[TBL] [Abstract][Full Text] [Related]
14. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
[TBL] [Abstract][Full Text] [Related]
16. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Sun J; Tan CJ; Dai Z
Expert Opin Investig Drugs; 2009 Nov; 18(11):1595-604. PubMed ID: 19780708
[TBL] [Abstract][Full Text] [Related]
18. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
[TBL] [Abstract][Full Text] [Related]
20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
